{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T21:51:51Z","timestamp":1791669111464,"version":"4.3.4"},"reference-count":38,"publisher":"BMJ","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Eur J Hosp Pharm"],"accepted":{"date-parts":[[2025,12,16]]},"DOI":"10.1136\/ejhpharm-2025-004639","type":"journal-article","created":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T18:20:25Z","timestamp":1767896425000},"page":"ejhpharm-2025-004639","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Association of acamprosate versus gabapentinoids with liver disease progression and alcohol-related admissions in patients with alcohol use disorder"],"prefix":"10.1136","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-6713-8784","authenticated-orcid":false,"given":"Raj","family":"Shah","sequence":"first","affiliation":[{"name":"Orlando VA Healthcare System, Orlando, Florida, USA"},{"name":"Department of Internal Medicine, University of Central Florida College of Medicine, Orlando, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-0789-7353","authenticated-orcid":false,"given":"Kirsten","family":"Zelneronok","sequence":"additional","affiliation":[{"name":"Orlando VA Healthcare System, Orlando, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-5106-8473","authenticated-orcid":false,"given":"Richard","family":"Henriquez","sequence":"additional","affiliation":[{"name":"Orlando VA Healthcare System, Orlando, Florida, USA"},{"name":"Department of Internal Medicine, University of Central Florida College of Medicine, Orlando, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6122-3716","authenticated-orcid":false,"given":"Ishak A","family":"Mansi","sequence":"additional","affiliation":[{"name":"Orlando VA Healthcare System, Orlando, Florida, USA"},{"name":"Department of Internal Medicine, University of Central Florida College of Medicine, Orlando, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,1,8]]},"reference":[{"key":"2026010810201576000_ejhpharm-2025-004639v1.1","unstructured":"Alcohol facts and statistics. Available: https:\/\/www.niaaa.nih.gov\/publications\/brochures-and-fact-sheets\/alcohol-facts-and-statistics [Accessed 16 May 2024]."},{"key":"2026010810201576000_ejhpharm-2025-004639v1.2","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000000380"},{"key":"2026010810201576000_ejhpharm-2025-004639v1.3","unstructured":"Chen CM , Yoon Y-H . Surveillance report# 118 liver cirrhosis mortality in the United States: National, State, and regional trends, 2000\u20132019. 2022."},{"key":"2026010810201576000_ejhpharm-2025-004639v1.4","doi-asserted-by":"publisher","DOI":"10.1002\/hep.31042"},{"key":"2026010810201576000_ejhpharm-2025-004639v1.5","doi-asserted-by":"publisher","DOI":"10.1111\/acer.13944"},{"key":"2026010810201576000_ejhpharm-2025-004639v1.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2008.07.018"},{"key":"2026010810201576000_ejhpharm-2025-004639v1.7","doi-asserted-by":"publisher","DOI":"10.1370\/afm.2997"},{"key":"2026010810201576000_ejhpharm-2025-004639v1.8","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.13014","article-title":"Incidence and Progression of Alcohol-Associated Liver Disease After Medical Therapy for Alcohol Use Disorder","volume":"5","author":"Vannier","year":"2022","journal-title":"JAMA Netw Open"},{"key":"2026010810201576000_ejhpharm-2025-004639v1.9","article-title":"Acamprosate for alcohol dependence","volume":"2010","author":"R\u00f6sner","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"2026010810201576000_ejhpharm-2025-004639v1.10","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v68n1108"},{"key":"2026010810201576000_ejhpharm-2025-004639v1.11","doi-asserted-by":"publisher","DOI":"10.1177\/0269881109102623"},{"key":"2026010810201576000_ejhpharm-2025-004639v1.12","doi-asserted-by":"crossref","first-page":"S1005","DOI":"10.14309\/01.ajg.0000954908.27192.4f","article-title":"S1317\u2003Impact of Pharmacologic Treatment for Alcohol Use Disorder on Mortality in Patients With Alcohol-Associated Liver Disease: Analysis From a United States Insurance Claims Database","volume":"118","author":"Harris","year":"2023","journal-title":"Am J Gastroenterol"},{"key":"2026010810201576000_ejhpharm-2025-004639v1.13","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1001\/jamainternmed.2017.7856","article-title":"Gabapentinoid Use in the United States 2002 Through 2015","volume":"178","author":"Johansen","year":"2018","journal-title":"JAMA Intern Med"},{"key":"2026010810201576000_ejhpharm-2025-004639v1.14","first-page":"S17","article-title":"Clinical pharmacokinetics of gabapentin","volume":"44","author":"McLean","year":"1994","journal-title":"Neurology (ECronicon)"},{"key":"2026010810201576000_ejhpharm-2025-004639v1.15","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12070"},{"key":"2026010810201576000_ejhpharm-2025-004639v1.16","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/j.1530-0277.2012.01937.x","article-title":"Comparing alcohol screening measures among HIV-infected and -uninfected men","volume":"37","author":"McGinnis","year":"2013","journal-title":"Alcohol Clin Exp Res Mar"},{"key":"2026010810201576000_ejhpharm-2025-004639v1.17","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s40471-015-0053-5","article-title":"The active comparator, new user study design in pharmacoepidemiology: historical foundations and contemporary application","volume":"2","author":"Lund","year":"2015","journal-title":"Curr Epidemiol Rep Dec"},{"key":"2026010810201576000_ejhpharm-2025-004639v1.18","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwm324"},{"key":"2026010810201576000_ejhpharm-2025-004639v1.19","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1097\/EDE.0b013e3181d61eeb","article-title":"Negative controls: a tool for detecting confounding and bias in observational studies","volume":"21","author":"Lipsitch","year":"2010","journal-title":"Epidemiology May"},{"key":"2026010810201576000_ejhpharm-2025-004639v1.20","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jsat.2015.01.002","article-title":"Examining the Specification Validity of the HEDIS Quality Measures for Substance Use Disorders","volume":"53","author":"Harris","year":"2015","journal-title":"J Subst Abuse Treat"},{"key":"2026010810201576000_ejhpharm-2025-004639v1.21","doi-asserted-by":"crossref","DOI":"10.1186\/1472-6963-11-73","article-title":"Validation of the treatment identification strategy of the HEDIS addiction quality measures: concordance with medical record review","volume":"11","author":"Harris","year":"2011","journal-title":"BMC Health Serv Res"},{"key":"2026010810201576000_ejhpharm-2025-004639v1.22","doi-asserted-by":"publisher","DOI":"10.1002\/hep.31726"},{"key":"2026010810201576000_ejhpharm-2025-004639v1.23","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2012.96867"},{"key":"2026010810201576000_ejhpharm-2025-004639v1.24","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2007020199"},{"key":"2026010810201576000_ejhpharm-2025-004639v1.25","doi-asserted-by":"publisher","DOI":"10.1111\/1475-6773.00165"},{"key":"2026010810201576000_ejhpharm-2025-004639v1.26","doi-asserted-by":"publisher","DOI":"10.1016\/0895-4356(92)90133-8"},{"key":"2026010810201576000_ejhpharm-2025-004639v1.27","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1177\/1536867X0200200403","article-title":"Estimation of Average Treatment Effects Based on Propensity Scores","volume":"2","author":"Becker","year":"2002","journal-title":"The Stata Journal: Promoting communications on statistics and Stata"},{"key":"2026010810201576000_ejhpharm-2025-004639v1.28","unstructured":"Leuven E , Sianesi B . PSMATCH2: stata module to perform full mahalanobis and propensity score matching, common support graphing, and covariate imbalance testing. 2003. Available: http:\/\/ideas.repec.org\/c\/boc\/bocode\/s432001.html"},{"key":"2026010810201576000_ejhpharm-2025-004639v1.29","doi-asserted-by":"crossref","unstructured":"Difference ACM . Standardized Mean Difference (SMD), and Their Use in Meta-Analysis: As Simple as It Gets. J Clin Psychiatry Sep 2020;81. doi:10.4088\/JCP.20f13681","DOI":"10.4088\/JCP.20f13681"},{"key":"2026010810201576000_ejhpharm-2025-004639v1.30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/hup.2751","article-title":"Gabapentinoids for treatment of alcohol use disorder: A systematic review and meta-analysis","volume":"35","author":"Cheng","year":"2020","journal-title":"Hum Psychopharmacol"},{"key":"2026010810201576000_ejhpharm-2025-004639v1.31","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s40429-022-00432-9","article-title":"Helpful or Harmful? The Therapeutic Potential of Medications with Varying Degrees of Abuse Liability in the Treatment of Substance Use Disorders","volume":"9","author":"Martins","year":"2022","journal-title":"Curr Addict Rep"},{"key":"2026010810201576000_ejhpharm-2025-004639v1.32","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2018.1417383"},{"key":"2026010810201576000_ejhpharm-2025-004639v1.33","article-title":"Alcoholics Anonymous and other 12-step programs for alcohol use disorder","volume":"3","author":"Kelly","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"2026010810201576000_ejhpharm-2025-004639v1.34","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1111\/add.13590","article-title":"Is Alcoholics Anonymous religious, spiritual, neither? Findings from 25 years of mechanisms of behavior change research","volume":"112","author":"Kelly","year":"2017","journal-title":"Addiction"},{"key":"2026010810201576000_ejhpharm-2025-004639v1.35","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1037\/prj0000334","article-title":"A pilot study comparing peer supported web-based CBT to self-managed web CBT for primary care veterans with PTSD and hazardous alcohol use","volume":"42","author":"Possemato","year":"2019","journal-title":"Psychiatr Rehabil J"},{"key":"2026010810201576000_ejhpharm-2025-004639v1.36","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2016.01.003"},{"key":"2026010810201576000_ejhpharm-2025-004639v1.37","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1080\/00952990.2017.1306747","article-title":"Combining medically assisted treatment and Twelve-Step programming: a perspective and review","volume":"44","author":"Galanter","year":"2018","journal-title":"Am J Drug Alcohol Abuse"},{"key":"2026010810201576000_ejhpharm-2025-004639v1.38","doi-asserted-by":"publisher","DOI":"10.1016\/j.addbeh.2009.03.014"}],"container-title":["European Journal of Hospital Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ejhpharm-2025-004639","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T18:20:27Z","timestamp":1767896427000},"score":1,"resource":{"primary":{"URL":"https:\/\/ejhp.bmj.com\/lookup\/doi\/10.1136\/ejhpharm-2025-004639"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,8]]},"references-count":38,"alternative-id":["10.1136\/ejhpharm-2025-004639"],"URL":"https:\/\/doi.org\/10.1136\/ejhpharm-2025-004639","relation":{},"ISSN":["2047-9956","2047-9964"],"issn-type":[{"value":"2047-9956","type":"print"},{"value":"2047-9964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,8]]}}}